Adma Biologics Inc. (ADMA)
NASDAQ (NMS) NASDAQ (NMS) Primary 
The Schall Law Firm Wants Shareholders To Take Part In An Inquiry Launched Into ADMA Biologics Inc For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / November 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why
Adma Biologics (ADMA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
ADMA Biologics, Inc. Is Being Investigated For Defrauding Investors And Those With Losses Are Urged To Reach Out To The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
The Schall Law Firm Invites Stockholders To Help With An Inquiry Into ADMA Biologics Inc's Securities Related Infractions
LOS ANGELES, CA / ACCESSWIRE / November 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
The Schall Law Firm Urges Shareholders To Join An Inquiry Into ADMA Biologics, Inc. For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / November 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
ADMA Biologics, Inc. (ADMA) Q3 2024 Earnings Call Transcript
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Skyler Bloom – Senior Director, Business Development & Corporate Strategy Adam Grossman – President and Chief Executive Officer Brad Tade – Chief Financial Officer and Treasurer Conference Call Participants Kristen Kluska – Cantor Fitzgerald Anthony Petrone – Mizuho Group Gary Nachman – Raymond James Operator Thank you for standing by. My name is Celine and I will be your conference operator today.
Adma Biologics (ADMA) Q3 Earnings and Revenues Beat Estimates
Adma Biologics (ADMA) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.01 per share a year ago.
Did ADMA Biologics (ADMA) Commit Securities Fraud Resulting in 20% Stock Drop? Contact BFA Law about its Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting Click Here
ADMA Biologics Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ:ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
ADMA STOCK ALERT: Why is ADMA Biologics Under Investigation for Securities Fraud? Contact BFA Law if You Lost Money on Your Investment (Nasdaq:ADMA)
NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting Click Here
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into ADMA Biologics, Inc. For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / November 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
